Table 1 Patients’ characteristics according to cytogenetic risk groups

Age at diagnosis, mean (±SD)

64.4 (± 9.4)

67.8 (± 8.2)

64.9 (± 10.7)

NS

Age at study entry, mean (±SD)

68.7 (± 9.3)

72.2 (± 8.4)

69.7 (± 9.8)

NS

Binet stage, No. of patients (%)

0.05

 A

50/64 (78.1%)

11/19 (57.9%)

16/30 (51.7%)

 B

8/64 (12.5%)

5/19 (26.3%)

11/30 (37.9%)

 C

6/64 (9.4%)

3/19 (15.8%)

3/30 (10.3%)

Lymphocytosis (Giga/L), mean (±SD)

30.7 (± 29.3)

74.7 (± 71.1)

49.6 (± 40.60)

0.006

IGHV mutational status, No. of patients (%)

NS

Unmutated (≥ 98% homology)

1/22 (4.5%)

2/12 (16.7%)

3/10 (30%)

Mutated (< 98% homology)

21/22 (95.5%)

10/12 (83.3%)

7/10 (70%)

CD38 > 30%, No. of patients (%)

12/58 (20.7%)

9/19 (47.4%)

6/25 (24%)

NS

LDT from diagnosis, median (months)^a

48

24

17

0.0004

PFS, median (months)^a

> 120

72

40

0.003

TFS, median (months)^a

> 120

77

72

0.001